EHA 2019 | BET Inhibitor CPI-0610 and ruxolitinib for myelofibrosis

Srdan Verstovsek

Here, Srdan Verstovsek, MD, PhD, from the University of Texas MD Anderson Cancer Center, Houston, TX, presents updates on the use of the BET Inhibitor CPI-0610 in combination with ruxolitinib for myelofibrosis. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter